Serum IGF1 on Female HFpEF Patients

Study Title: Application of Serum IGF1 in the Diagnosis of Female Heart Failure with Preserved Ejection Fraction (HFpEF) Study Institution: Hong Kong University-Shenzhen Hospital Principal Investigator: Sidong Cai 1. Study Purpose This study aims to investigate whether serum insulin-like growth factor 1 (IGF1) can be used to improve the diagnosis of heart failure with preserved ejection fraction (HFpEF) in women, providing preliminary insights for early detection of this condition in female patients. 2. Study Procedures Information Collection: Relevant medical information will be collected during your outpatient visit or hospitalization. Subject Identification: If you agree to participate, you will be assigned a unique study number to establish a medical record file. Blood Sampling: Blood samples will be collected concurrently with routine clinical blood draws (no additional needle insertions). Volume: 10-20 mL of venous blood each time, collected on the enrollment day, 3 months, 6 months, and 12 months after enrollment. Use of Samples: Samples will be used exclusively for this study. Follow-up Examinations: Standard HF follow-up tests (e.g., echocardiograms) will be conducted as clinically necessary. These are part of routine HF management and will not impose extra burden on you. 3. Risks and Discomforts Confidentiality: All information will be kept strictly confidential. Minimal Risks: Temporary pain, bruising, or tenderness at the blood draw site. Rarely, mild dizziness or (extremely rarely) needle site infection. 4. Responsibilities as a Research Subject You are required to: Provide truthful information about your medical history and current health status. Report any discomfort experienced during the study to the research doctor. Avoid taking restricted medications or foods as instructed. Disclose if you are currently participating in, or have recently participated in, other research studies. 5. Privacy Protection Anonymizati